33407-02-2

Usage

Physical state

Colorless liquid

Structure

Chlorinated benzene ring with an ethyl group attached

Uses

a. Intermediate in the production of agricultural chemicals
b. Intermediate in the production of pharmaceuticals
c. Solvent
d. Manufacturing of other organic compounds

Toxicity

Moderately toxic

Health hazards

a. Skin irritation
b. Eye irritation
c. Respiratory system irritation

Safety measures

Handle with care and use appropriate safety measures when working with it

Upstream product

• 2040-05-3 2,6 dichloroacetophenone 
• 28469-92-3 2,6-dichlorostyrene 
• 19393-92-1 1-bromo-2,6-dichlorobenzene 
• 557-20-0 diethylzinc 
• 64-67-5 diethyl sulfate 
• 541-73-1 1,3-Dichlorobenzene 
• 1194-65-6 2,6-dichloro-benzonitrile 
• 258345-73-2 1,3-dichloro-2-(1,2-dibromoethyl)benzene 
• 74-85-1 ethene 

Downstream Products

• 1227417-88-0 3-chloro-2-ethylphenol 
• 16281-98-4 1-(2,6-Dicarbomethoxy-phenyl)-aethylbromid 
• 258345-76-5 1-(2,4-dichloro-3-ethylphenyl)ethanone 
• 20444-00-2 1,3-dichloro-2-(1-bromoethyl)benzene 

Relevant academic research and scientific papers

Alkylation of dichlorobenzene isomers by olefins on zeolites Y and pentasil

Catalytic alkylation of dichlorobenzene isomers by ethylene and propylene on zeolite catalysts has been studied.It has been determined that using catalysts based on zeolite Y makes it possible to change the ratio of 1-alkyldichlorobenzenes formed within a wide range by varying the acidic properties of the catalysts. - Keywords: alkylation, dichlorobenzenes, olefins, zeolites

INHIBITORS OF FATTY ACID BINDING PROTEIN (FABP)

The present invention relates to novel heterocyclic compounds as Fatty Acid Binding Protein ("FABP") inhibitors, pharmaceutical compositions comprising the heterocyclic compounds and the use of the compounds for treating or preventing a cardiovascular disease, a metabolic disorder, obesity or an obesity-related disorder, diabetes, dyslipidemia, a diabetic complication, impaired glucose tolerance or impaired fasting glucose. An illustrative compound of the present invention is shown below: (I)

Proton mobility in 2-substituted 1,3-dichlorobenzenes: "ortho" or "meta" metalation?

Nine 1,3-dichlorobenzene congeners were selected as model compounds to assess the relative rates of proton abstraction from 4- and 5-positions ("ortho" vs. "meta" metalation). Using lithium 2,2,6,6-tetramethylpiperidide as the basic reagent, the chlorine-adjacent 4-position underwent metalation exclusively. In contrast, attack at the chlorine-remote 5-posi" tion became significant even in the case of moderately sized 2-substituents (such as dimethylamino or ethyl) when secbutyllithium was employed. The "ortho/para" (4-/5-) ratios ranged from 80:20 to 65:35. The more pronounced "meta-orienting" effect of silicon as opposed to carbon substituents can be attributed to dissimilarities in the n polarization of the aromatic ring. Wiley-VCH Verlag GmbH & Co. KGaA, 2006.

Negishi-type coupling of bromoarenes with dimethylzinc

Treatment of bromoarenes with dimethylzinc in the presence of a palladium catalyst provides a high-yielding route to methylarenes. The process accommodates a wide range of aromatic substituents and, in the majority of cases, is free of side reactions.

Studies on 6-aminoquinolones: Synthesis and antibacterial evaluation of 6-amino-8-ethyl- and 6-amino-8-methoxyquinolones

From our quantitative structure-activity relationship (QSAR) study on a large set of 6-aminoquinolones, which indicated that a group larger than methyl could be allocated at C-8 position, we have synthesized two new series of 6-aminoquinolones characteriz